Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments

BACKGROUND: Vaccination against SARS CoV-2 results in excellent personal protection against a severe course of COVID19. In People with Multiple Sclerosis (PwMS) vaccination efficacy may be reduced by immunomodulatory medications. OBJECTIVE: To assess the vaccination induced cellular and humoral immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bock, H., Juretzek, T., Handreka, R., Ruhnau, J., Löbel, M., Reuner, K., Peltroche, H., Dressel, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783535/
https://www.ncbi.nlm.nih.gov/pubmed/35180617
http://dx.doi.org/10.1016/j.msard.2022.103554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783535/
https://www.ncbi.nlm.nih.gov/pubmed/35180617
http://dx.doi.org/10.1016/j.msard.2022.103554

Ejemplares similares